Remon Helmy is a Senior Manager, Health Economics and Outcomes Research at Alexion, AstraZeneca Rare Disease Business Unit. He is a registered pharmacist with a master’s degree in Health Economics from the University of Heidelberg, Germany and a PhD with a focus on Treatment Adherence from the University of Basel, Switzerland. He also holds a Master of Business Administration. He has over 14 years of experience across different settings of pharmacy practice, academia, consulting, and the pharmaceutical industry.
Shahbaz Pervaiz is RWE Services Director at LynxCare. He has close to a decade of experience in RWE studies (previously at IQVIA) and has a strong track-record supporting global pharma companies with their market access, pricing, product launch preparation and understanding of the patient journey.
Ivan Clement is currently the Global Associate Director, RWE & Innovative Evidence in Neuroscience in Novartis, where he is responsible for the development and implementation of scientifically robust Integrated Evidence Strategies that drive successful launch, access, and clinical adoption of portfolio drug assets. He brings over 10 years of experience in evidence generation across the pharma lifecycle and in multiple therapeutic areas – starting in Eli Lilly where he supported key clinical development programs in neuroscience, oncology, and immunology, and then subsequently in MSD where he led digital health, access, and RWE analytics activities for their immuno-oncology and vaccines portfolio. He then established RWD collaborative partnership ecosystems in Asia-Pacific while in IQVIA, prior to leading portfolio data and evidence generation strategic initiatives in Roche.
Veronika Schweighart is a serial entrepreneur with work experience in business development, strategic marketing and technology consulting. As Co-Founder and COO of Climedo, she oversees Key Account Management, Innovation and Partnerships, and is passionate about demonstrating the power of digital technologies to healthcare professionals.
Sandeep Kiri has over thirteen years of experience in market access with a strong focus on health economics and health technology assessment. He has been in the global function at UCB for five years and is currently the Global Head of Health Economics and HTA Evidence with a keen focus on developing the right evidence for payers in order to demonstrate the full value of interventions.
Dr. Michael Happich is Senior Director - Value Evidence Outcomes Intl - at Eli Lilly based in Bad Homburg, Germany. He leads an international team of HTA & RWE scientists to support drug launches, HTA submissions and observational research for autoimmune diseases outside the US. Before joining the industry 18 years ago, he worked at the Helmholtz-Research Center in Munich. He is lecturer on pharmacoeconomics at the Goethe University Frankfurt, and Neubrandenburg University of applied sciences.
Alexandre Templier has been working in the field of Life Sciences for more than 28 years. Passionate about Artificial Intelligence and data-driven decision-making in complex environments, Alexandre has dedicated his professional career to improving healthcare products and medical practice through Real World Data analytics and AI. Co-founder of Quinten Health and President of Quinten Health, he is particularly involved in the development of Quinten Health's activities within the healthcare sector (including projects for industry, healthcare providers, research institutions, and healthcare regulatory agencies). Alexandre was associate professor at Ecole Nationale Supérieure d'Arts & Métiers Paris Tech from 2001 to 2013.
.png)
Christian is a consultant pharmacist for medical information. He holds a Diploma in pharmaceutical technology from University of Leipzig and PhD in Medical Sciences of Charité University Medicine of Berlin. After several years working in public pharmacies, he joined Riemser Arzneimittel AG as Medical Advisor. He gained broad experiences in Medical Information, Medical Marketing, Clinical Operations and as Information officer. From 2012 to 2014 he has set up the German Operational Business Unit of LA-SER Analytica, a French CRO specialized in the management of pharmacoepidemiological studies. In 2014 he took over the responsibility of Non-Interventional Studies Team and in 2018 the responsibility of Data Generation Team of BAYER Vital GmbH in Leverkusen, Germany. In this position he drives digitalization and innovation in observational study conduct at BAYER. By leveraging innovative methodologies, his range of activity is from the development of data collection tools to measure adherence, explore eConsent, conduct investigator free fully digital studies or automatize data transfer from EHR2EDC.
Alberto is Global business developer for Savana. He worked extensively during his 10 years of professional career in different marketing and business development positions, highlighting his experience in evidence generation, RWD and artificial intelligence thanks to his current activity in Savana.Alberto is Pharmacist by training, with a remarkable experience in the life Sciences sector and a MBA in the Pharmaceutical Industry by the University of Barcelona.
Experienced leader in HEOR field with deep understanding of local and national payer’s needs, with a track record of unique initiatives which lead to sustainable impact for the brand, the companies, the HCPs and ultimately to the patients. Helene is driven by improving health management of chronic conditions/ oncology and optimizing treatment pathway by deep understand of health data and their use with internal and external governance.
Dr Davy Yeung’s career to date encompasses academia and the NHS. He has made valuable contributions to clinical research at the University of Cambridge, Imperial College, and other major academic institutions.
Dr Yeung was also the Head of Research at various UK Hospital Trusts. During his time in the NHS, he gained considerable insight into the governance and delivery of clinical research in the UK. This unique perspective enables our sponsors to select, initiate and manage UK investigative sites for their clinical studies rapidly and effectively. Having collaborated with a wide range of influential leaders in the field of clinical research, Dr Yeung is himself highly respected and well known in the UK’s healthcare research and development sector.
Remon Helmy is a Senior Manager, Health Economics and Outcomes Research at Alexion, AstraZeneca Rare Disease Business Unit. He is a registered pharmacist with a master’s degree in Health Economics from the University of Heidelberg, Germany and a PhD with a focus on Treatment Adherence from the University of Basel, Switzerland. He also holds a Master of Business Administration. He has over 14 years of experience across different settings of pharmacy practice, academia, consulting, and the pharmaceutical industry.
Meritxell Sabidó is Director at Global Epidemiology Department, Neurology and Immunology Group - Merck Healthcare KGaA (Germany). She has worked extensively with Real Word Data and led regulatory studies based on registries and other data sources for the last 10 years. Meritxell is an MD specialized in Preventive Medicine and Public Health and has a PhD in Epidemiology.
Anila has over two decades of experience driven value in business decisions through strategic thought leadership and meaningful evidence generation. Her professional career began with conducting real world evidence (RWE ) research in Greece followed by several roles leading European and global pharma or CRO teams and observational research programs. Currently holds the position of Executive of Real-World Evidence (RWE) at SyneosHealth, where she provides strategy and leadership across strategic programs of multiple pharma or biotech clients, developing innovative real-world data platforms for integrated evidence generation planning throughout asset development and commercialization.
Anila is a respected RWLP advocate and often engages in presentations at industry webinars and conferences.She holds a Bachelor in Optometry from Athens Institute of Technology, and MBA from University of Indianapolis and a PHD in strategic Marketing.
Oisin Butler is the Integrated Evidence Generation Lead for Bayer Radiology. In this role, Oisin is responsible for evidence generation needs leveraging Real World Data (RWD) and Real World Evidence (RWE), serving all elements of the Bayer Radiology portfolio.
Oisin received his MSc from the Institute of Psychiatry, Kings College London and his PhD in Neuroscience from Humboldt University and the Max Planck Institute for Human Development in Berlin, where he focused on neuroimaging research.
Dries Hens, M.D. is Chief Medical Officer and co-founder of LynxCare, a healthcare Big Data company on a mission to unlock clinical data. Dries is a medical doctor (KU Leuven, Belgium) with an MBA in Pharmaceutical Management (ESCP Europe, Paris). He is passionate about (new) business models where technology supports healthcare providers to deliver safer and more efficient healthcare, particularly in creating multistakeholder ecosystems fueled by outcome data.
Michael is the Founder and CEO of Red Door Analytics, an independent biostatistics consultancy company based in Stockholm, Sweden. Michael is an internationally renowned biostatistician and software developer, with particular expertise in complex analysis of observational data. He is a former Associate Professor of Biostatistics at the University of Leicester, a former NIHR Fellow and MRC New Investigator, and a co-author of NICE TSD 21: Flexible methods for survival analysis. He also teaches advanced statistics courses globally, particularly in joint modelling and multi-state survival analysis.
